Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.4.1431

Role of HER2 in Brain Metastasis of Breast Cancer: a Systematic Review and Meta-Analysis  

Hedayatizadeh-Omran, Akbar (Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences)
Rafiei, Alireza (Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences)
Alizadeh-Navaei, Reza (Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences)
Tehrani, Mohsen (Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences)
Valadan, Reza (Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences)
Moradzadeh, Kambiz (Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences)
Panbechi, Mohammad (Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences)
Taghavi, Seyed Mehdi (Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.4, 2015 , pp. 1431-1434 More about this Journal
Abstract
Background: Breast cancer is one of the most common cancers among women worldwide and the HER2 receptor plays an important role in its development and progression. This systematic review aimed to summarize the role of HER2 in brain metastasis in patients with breast cancer. Materials and Methods: We conducted a literature search by advanced search in title field using the Scopus, Pubmed, and Google scholar databases until the end of June 2014. With metastasis, metastatic, HER2, brain, and breast cancer, as terms of search we selected 31 articles, which were reviewed by two independent and blinded expert reviewers. The studies were first selected according to their titles and abstracts. Quality of the studies were then assessed using the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) protocol for observational studies and CONSORT(Consolidation of Standards for Reporting Trials) protocol for clinical trials. For statistical analyses, we used STATA, version 11.0 software. Forest and funnel diagrams were drawn and for heterogeneity, index was also considered. Also we used meta regression analysis. Results: Finally, we reviewed 10 studies. The prevalence of brain metastasis in HER2-positive breast cancer patients was 24.9%. There was publication bias in the reviewed studies. Meta regression analysis showed that follow up time had no significant effect (p=0.396) on the prevalence of brain metastasis. Conclusions: The results showed a high prevalence of brain metastasis in HER2 positive breast cancer patients.
Keywords
HER2; brain metastasis; breast cancer;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Ajami A, Rafiei A, Naghshvar F, et al (2009). Association of human leukocyte antigen and esophageal cancer in North of Iran. Pak J Biol Sci, 12, 1585-8.   DOI
2 Akhavan A, Binesh F, Heidari S (2014). Survival of brain metastatic patients in Yazd, Iran. Asian Pac J Cancer Prev, 15, 3571-4.   DOI
3 Brufsky AM, Mayer M, Rugo HS, et al (2011). Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res, 17, 4834-43.   DOI
4 Demircioglu F, Demirci U, Akmansu M (2013). Lymph node ratio assessment of brain metastasis in early breast cancer cases. Asian Pac J Cancer Prev, 14, 1665-7.   DOI
5 Duchnowska R, Szczylik C (2005). Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev, 31, 312-8.   DOI
6 Gabos Z, Sinha R, Hanson J, et al (2006). Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol, 24, 5658-63.   DOI
7 Holloway PJ, Worthington HV (2002). What is CONSORT? How to publish a research project. Health Education J, 61, 293-8.   DOI
8 Lin NU, Winer EP (2007). Brain metastases: the HER2 paradigm. Clin Cancer Res, 13, 1648-55.   DOI
9 Lu D, Zhang H, Koo H, et al (2005). A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem, 280, 19665-72.   DOI
10 Pazhoomand R, Keyhani E, Banan M, et al (2013). Detection of HER2 status in breast cancer: comparison of current methods with MLPA and real-time RT-PCR. Asian Pac J Cancer Prev, 14, 7621-8.   DOI
11 Saip P, Cicin I, Eralp Y, et al (2008). Factors affecting the prognosis of breast cancer patients with brain metastases. Breast, 17, 451-8.   DOI
12 Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.   DOI
13 Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70.   DOI   ScienceOn
14 Tomasello G, Bedard PL, de Azambuja E, et al (2010). Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit Rev Oncol Hematol, 75, 110-21.   DOI
15 von Elm E, Altman DG, Egger M, et al (2007). The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull WHO, 85, 867-72.
16 Yarden Y (2001). The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer, 37, 3-8.
17 Yau T, Swanton C, Chua S, et al (2006). Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol, 45, 196-201.   DOI